-
UnitedHealth Group Incorporated (DE) (UNH $267.09)
- $267.09 P/E (TTM): 14.82X Cap: $249.93B
- View UNH Profile
- View Questions on UNH
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
UnitedHealth Group Incorporated (DE) (UNH $267.09)
- $267.09 P/E (TTM): 14.82X Cap: $249.93B
- View UNH Profile
- View Questions on UNH
Q: Hello, can you comment on their latest earnings? Thanks
-
UnitedHealth Group Incorporated (DE) (UNH $267.09)
- $267.09 P/E (TTM): 14.82X Cap: $249.93B
- View UNH Profile
- View Questions on UNH
Q: UNH appears to be in something of a no-man’s-land for the next year or two. An RBC DS report on January 21 says “intermediate-term recovery seems already priced in ” which suggests limited near-term upside. Disagree? I don't mean to prejudice your answer, but FYI CFRA also seems unimpressed with UNH’s prospects.
I’d appreciate your view on:
• Do you agree that UNH offers limited upside over the next 12–24 months, or do you see catalysts the market is missing?
• Have large loss which is not usable for tax. Would that factor into your hold vs. exit decision?
• If you believe UNH is still worth holding, please outline your rationale.
What do you show for current , updated forward P/E, PEG, and debt levels?
• More broadly, do you think the current U.S. administration and regulatory stance will constrain UNH’s ability to grow, and is there any risk that the core business model is now structurally impaired?
Many thanks! :ao:
I’d appreciate your view on:
• Do you agree that UNH offers limited upside over the next 12–24 months, or do you see catalysts the market is missing?
• Have large loss which is not usable for tax. Would that factor into your hold vs. exit decision?
• If you believe UNH is still worth holding, please outline your rationale.
What do you show for current , updated forward P/E, PEG, and debt levels?
• More broadly, do you think the current U.S. administration and regulatory stance will constrain UNH’s ability to grow, and is there any risk that the core business model is now structurally impaired?
Many thanks! :ao:
-
Pfizer Inc. (PFE $26.77)
- $26.77 P/E (TTM): 14.98X Cap: $152.26B
- View PFE Profile
- View Questions on PFE
-
UnitedHealth Group Incorporated (DE) (UNH $267.09)
- $267.09 P/E (TTM): 14.82X Cap: $249.93B
- View UNH Profile
- View Questions on UNH
-
The Trade Desk Inc. (TTD $26.13)
- $26.13 P/E (TTM): 31.24X Cap: $13.18B
- View TTD Profile
- View Questions on TTD
-
JD.com Inc. (JD $27.37)
- $27.37 P/E (TTM): 7.28X Cap: $40.03B
- View JD Profile
- View Questions on JD
Q: Hello
it was mentioned that Peter would give his thoughts of some of the stocks on TSX that would be candidates for a rebound in 2026, on National Post on Dec 20 , I have missed seeing that, can you let me know what are some of the stocks that he like for a rebound after a disappointing 2025 year? thanks
Michael
it was mentioned that Peter would give his thoughts of some of the stocks on TSX that would be candidates for a rebound in 2026, on National Post on Dec 20 , I have missed seeing that, can you let me know what are some of the stocks that he like for a rebound after a disappointing 2025 year? thanks
Michael
Insiders
Share Information
SEC Filings
News and Media